# US 2013/0157289 A1 · Immuno-pet imaging of antibodies and immunoconjugates and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157289 A1
- Document ID: US20130157289A1
- Status: Published application
- Kind: A1
- Application number: 13/692,888
- Filed: 2012-12-03
- Published: 2013-06-20
- Earliest claimed: 2010-06-03
- Assignees: Genentech, Inc.
- Inventors: Mark Dennis; Jan Marik; Paul Polakis; Bonnee Rubinfeld; Simon Williams
- Web page: https://patentgrep.com/patent/US20130157289A1

## CPC

- C07K 16/40: against enzymes
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 51/1072: {the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate}
- A61K 51/1075: {the antibody being against an enzyme}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- C07B 59/008: {Peptides; Proteins}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- G01N 33/534: with radioactive label
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/60: involving radioactive labelled substances
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.

## Claims

### Claim 1

A method of determining the presence of a STEAP-1 protein in a biological sample suspected of containing said STEAP-1 protein, said method comprising exposing said biological sample to a 89Zirconium-labeled anti-STEAP-1 antibody and determining binding of said 89Zirconium-labeled anti-STEAP-1 antibody to said protein in said biological sample, wherein binding of said 89Zirconium-labeled anti-STEAP-1 antibody to said protein is indicative of the presence of said STEAP-1 protein in said biological sample.

### Claim 2 (depends on 1)

The method of claim 1, which is an immuno-PET imaging method.

### Claim 3 (depends on 1)

The method of claim 1, which is conducted in a patient suspected of having a prostate, lung, colon, bladder, ovarian cell or Ewing's sarcoma cell proliferation disorder.

### Claim 4 (depends on 3)

The method of claim 3, wherein the patient is human.

### Claim 5 (depends on 1)

The method of claim 1, wherein the 89Zirconium-labeled anti-STEAP-1 antibody is 100 μCi 89Zr-anti-STEAP1 antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the 89Zirconium-labeled anti-STEAP-1 antibody comprises an antibody that binds to STEAP-1, wherein the antibody that binds to STEAP-1 comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:9 or 10 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6.

### Claim 6

A composition comprising a 89Zirconium-labeled anti-STEAP-1 antibody.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the 89Zirconium-labeled anti-STEAP-1 antibody comprises an antibody that binds to STEAP-1, wherein the antibody that binds to STEAP-1 comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:9 or 10 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6.